Activity 3: Glycan profiling of high abundance proteins in plasma and CSF in the development of Alzheimer’s disease.

 

Background/aim:

Glycosylation is one the most common post-translational modifications of proteins. It is considered to be a biologically very important and may impact protein folding, serum halflife and functional activity. Glycosylation contributes to the heterogeneity of proteins and there is a growing body of evidence that different diseases may affect the glycosylation of specific proteins.

This project will apply an automated and miniaturized microfluidic method, developed for glycan profiling of therapeutic antibodies, to the analysis of glycan patterns of proteins in plasma and CSF where the glycosylation pattern has been reported to change in relation to progression of Alzheimer’s disease. The microfluidic method is performed in microstructures on a Compact Disc (CD) that Gyros AB has developed specifically for this purpose. There are 54 parallel microstructures available on each disc and the sample processing takes in its simplest form approximately 2 hours to perform. The methodology makes use of affinity capture of proteins and ezymatic release of the glycans. The relative abundances of the released glycans are determined using MALDI-MS.
As the previously developed procedure is rapid and automated, we expect to be able to analyze a significant numbers of samples from relevant sample types to investigate the relationship between the glycan profile of the selected proteins and development of Alzheimer’s disease.

 

 

 

Project leader:

 

 

 

Participants:

 

  • Gunnar Thorsén (SU)

 

 

PARTNERS
Uppsala Berzelii Technology Centre for Neurodiagnostics | Email info@berzelii.uu.se